共 50 条
- [21] Enfortumab Vedotin in Advanced Urothelial CarcinomaNEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (01): : 93 - 94Petrylak, Daniel P.Powles, ThomasRosenberg, Jonathan E.
- [22] Enfortumab vedotin to treat urothelial carcinomaDRUGS OF TODAY, 2020, 56 (05) : 329 - 335Hanna, K. S.
- [23] Enfortumab vedotin - next game-changer in urothelial cancerEXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (07) : 801 - 809Maas, MoritzStuehler, ViktoriaWalz, SimonStenzl, ArnulfBedke, Jens
- [24] Treatment Approaches for Cisplatin-Ineligible Patients with Invasive Bladder CancerCurrent Treatment Options in Oncology, 2019, 20David J. EinsteinGuru Sonpavde
- [25] Enfortumab vedotin in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer who received prior PD-1/PD-L1 inhibitors: An updated analysis of EV-201 Cohort 2.JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)McGregor, Bradley AlexanderBalar, Arjun VasantRosenberg, Jonathan E.Van der Heijden, Michiel SimonPark, Se HoonLee, Jae-LyunKojima, TakahiroHarrison, Michael RogerHeath, Elisabeth I.Stein, Mark N.Loriot, YohannNecchi, AndreaSteinberg, Joyce LetaLiang, Shang-YingTrowbridge, JanetPetrylak, Daniel P.Yu, Evan Y.
- [26] PIVOT-10: Phase II study of bempegaldesleukin plus nivolumab in cisplatin-ineligible advanced urothelial cancerFUTURE ONCOLOGY, 2020, 17 (02) : 137 - 149Huddart, Robert A.Siefker-Radtke, Arlene O.Balar, Arjun, VBilen, Mehmet A.Powles, ThomasBamias, AristotelisCastellano, DanielKhalil, Maged F.van der Heijden, Michiel S.Koshkin, Vadim S.Pook, David W.Ozguroglu, MustafaSantiago, LindaZhong, BobChien, DavidLin, WeiTagliaferri, Mary A.Loriot, Yohann
- [27] Treatment Approaches for Cisplatin-Ineligible Patients with Invasive Bladder CancerCURRENT TREATMENT OPTIONS IN ONCOLOGY, 2019, 20 (02)Einstein, David J.Sonpavde, Guru
- [28] Neoadjuvant nivolumab (N) plus ipilimumab (I) in cisplatin-ineligible patients with upper tract urothelial cancer (UTUC).JOURNAL OF CLINICAL ONCOLOGY, 2023, 41Teo, Min YuenGuercio, Brendan JohnPietzak, Eugene J.Ponomarev, MariaRegazzi, Ashley M.Quinlan, ColleenAggen, David H.Donahue, Timothy F.Goh, Alvin C.Cha, Eugene K.Donat, S. MacheleDalbagni, GuidoBochner, Bernard H.Funt, Samuel A.Bajorin, Dean F.Iyer, GopaOstrovnaya, IrinaAl-Ahmadie, Hikmat A.Coleman, JonathanRosenberg, Jonathan E.
- [29] Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV-201): a multicentre, single-arm, phase 2 trialLANCET ONCOLOGY, 2021, 22 (06): : 872 - 882Yu, Evan Y.Petrylak, Daniel P.O'Donnell, Peter H.Lee, Jae-Lyunvan der Heijden, Michiel S.Loriot, YohannStein, Mark N.Necchi, AndreaKojima, TakahiroHarrison, Michael R.Park, Se HoonQuinn, David, IHeath, Elisabeth, IRosenberg, Jonathan E.Steinberg, JoyceLiang, Shang-YingTrowbridge, JanetCampbell, MaryMcGregor, BradleyBalar, Arjun, V
- [30] Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial CancerJOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (01) : 22 - +Hoimes, Christopher J.Flaig, Thomas W.Milowsky, Matthew, IFriedlander, Terence W.Bilen, Mehmet AsimGupta, ShilpaSrinivas, SandyMerchan, Jaime R.McKay, Rana R.Petrylak, Daniel P.Sasse, CarolynMoreno, Blanca HometYu, YaoCarret, Anne-SophieRosenberg, Jonathan E.